Super PiggyBac Transposase Expression Vector

Catalyze your PiggyBac genome engineering with this enhanced, hyperactive transposase that can insert any-length DNA segment into the genome
  • Make transgenic cell lines with a single transfection
  • Integrate multiple PiggyBac Vectors in a single transfection
  • Insert an expression cassette into human, mouse, and rat cells
  • Deliver virtually any-sized DNA insert, from 10 – 100 kb
  • Choose from PiggyBac Vectors that express your gene-of-interest from constitutive or inducible promoters and include a variety of markers

Products

Catalog Number Description Size Price Quantity Add to Cart
PB210PA-1 Super piggyBac Transposase expression vector (replaces PB200A-1) 10 µg $512
- +

Overview

Overview

Get easy, consistent transgenesis

At the heart of SBI’s PiggyBac Transposon System* is the Super PiggyBac Transposase, an engineered, hyperactive version of the enzyme that can efficiently integrate any-sized DNA insert into the genome.

Why use the PiggyBac Transposon System?

Easy, consistent transgenesis with no limits on cargo size—For transgenesis that’s easy, consistent, and not limited by cargo size, SBI’s PiggyBac Transposon System is an excellent choice. The system consists of a PiggyBac Vector and the Super PiggyBac Transposase which recognizes transposon-specific inverted terminal repeats (ITRs) and efficiently integrates the ITRs and intervening DNA into the genome at TTAA sites. The Super PiggyBac Transposase is delivered to the cell via the Super PiggyBac Transposase Expression Vector, which is co-transfected with one or more PiggyBac Vectors.

Footprint-free removal that leaves no PiggyBac sequences behind—In addition to ease-of-use, consistency, and the lack of limits on DNA insert size, what sets this system apart is the ability to reverse the integration reaction in a footprint-free way—with the Excision Only PiggyBac Transposase (Cat.# PB220PA-1), the ITRs and cargo that the Super PiggyBac Transposase integrates into the genome can be removed, leaving behind the original genomic sequence and nothing else.

  • Make transgenic cell lines with a single transfection
  • Integrate multiple PiggyBac Vectors in a single transfection
  • Insert an expression cassette into human, mouse, and rat cells
  • Deliver virtually any-sized DNA insert, from 10 – 100 kb
  • Choose from PiggyBac Vectors that express your gene-of-interest from constitutive or inducible promoters and include a variety of markers
  • Determine the number of integration events with the PiggyBac qPCR Copy Number Kit (Cat.# PBC100A-1)

Customer Agreements

Academic customers can purchase PiggyBac Transposon System components for internal research purposes for indefinite use, whereas commercial customers must sign a customer agreement for a six-month, limited-use license to evaluate the technology.

For end user license information, see the following:

* SBI is fully licensed to distribute PiggyBac vectors as a partnership with Hera BioLabs, Inc.

References

How It Works

How It Works

The PiggyBac Transposon System’s Cut-and-Paste Mechanism

The efficient PiggyBac Transposon System uses a cut-and-paste mechanism to transfer DNA from the PiggyBac Vector into the genome. If only temporary genomic integration is desired, the Excision-only PiggyBac Transposase can be transiently expressed for footprint-free removal of the insert, resulting in reconstitution of the original genome sequence.

The PiggyBac Transposon System’s cut-and-paste mechanism

Figure 1. The PiggyBac Transposon System’s cut-and-paste mechanism.

Step 1 The Super PiggyBac Transposase binds to specific inverted terminal repeats (ITRs) in the PiggyBac Cloning and Expression Vector and excises the ITRs and intervening DNA.

Step 2 The Super PiggyBac Transposase inserts the ITR-Expression Cassette-ITR segment into the genome at TTAA sites.

Step 3 The Excision-only Super PiggyBac Transposase can be used to remove the ITR-Expression Cassette-ITR segment from the genome, for footprint-free removal.

Supporting Data

Supporting Data

One transfection can integrate one or more genes that can be precisely removed

Efficient transgenesis with the Super PiggyBac Transposase and both single- and dual-promoter PiggyBac Vectors

 

Figure 2. Efficient transgenesis with the Super PiggyBac Transposase and both single- and dual-promoter PiggyBac Vectors. (Top four panels) Co-transfection with the Super PiggyBac Transposase Expression Vector (Cat.# PB210PA-1) and a Dual Promoter PiggyBac Cloning and Expression Vector (Cat.# PB513B-1) into HeLa cells demonstrates the efficient integration delivered by SBI’s PiggyBac Transposon System. After ten days of puromycin selection, only the cells co-transfected with the Super PiggyBac Transposase (+PB, right two panels) show robust growth and GFP fluorescence. (Bottom four panels) Co-transfection with the Super PiggyBac Transposase Expression Vector (Cat.# PB210PA-1) and a Single Promoter PiggyBac Cloning and Expression Vector (Cat.# PB531A-2) into HEK293 cells further demonstrates the efficient integration delivered by SBI’s PiggyBac Transposon System. After seven days of growth, the majority of cells that received the Super PiggyBac Transposase Expression Vector (+PB, right two panels) were RFP positive.

Simultaneous integration of multiple PiggyBac Vectors is also highly efficient

 

Figure 3. Simultaneous integration of multiple PiggyBac Vectors is also highly efficient. METHODS: Three different PiggyBac transposon vectors (Cat.# PB513B-1, Cat.# PB533A-2, and Cat.# PB531A-2) were co-transfected with (left panels) or without (right panels) the Super PiggyBac Transposase Expression Vector (Cat.# PB210PA-1) into Human HT1080 cells. Puromycin and neomycin selection was applied for seven days. The cells that were co-transfected with the Super PiggyBac Transposase Expression Vector were puro and neo resistant, GFP-positive, and RFP-positive. Background GFP-positive cells that are puro resistant stem from random PB513B-1 integrations during the puromycin selection. The non-PiggyBac-mediated integration rate in those cells was extremely low and no RFP-positive cells were identified.

FAQs

The Super PiggyBac Transposase Expression Vector is an engineered, hyperactive version of the enzyme used in SBI's PiggyBac Transposon System. It can efficiently integrate any-sized DNA insert into the genome, enabling easy and consistent transgenesis.
  • Delivery of virtually any-sized DNA insert, from 10 – 100 kb
  • Footprint-free removal that leaves no PiggyBac sequences behind
  • Ability to make transgenic cell lines with a single transfection
  • Capability to integrate multiple PiggyBac Vectors in a single transfection
  • Insertion of an expression cassette into human, mouse, and rat cells
  • Variety of PiggyBac Vectors with different promoters and markers
The PiggyBac Transposon System uses a cut-and-paste mechanism to transfer DNA from the PiggyBac Vector into the genome. The Super PiggyBac Transposase recognizes transposon-specific inverted terminal repeats (ITRs) and efficiently integrates the ITRs and intervening DNA into the genome at TTAA sites.
Yes, using the Excision Only PiggyBac Transposase (Cat. # PB220PA-1), the ITRs and cargo that the Super PiggyBac Transposase integrates into the genome can be removed in a footprint-free way, leaving behind the original genomic sequence and nothing else.
Academic customers can purchase PiggyBac Transposon System components for internal research purposes for indefinite use. Commercial customers must sign a customer agreement for a six-month, limited-use license to evaluate the technology. End-user license information can be found on the respective pages for academic and commercial customers.
You can contact a specialist by visiting the Contact Us page or calling 1-(888) 640-4371.

Resources

Citations

  • Brouwer, I, de Kort, MAC & Lenstra, TL. (2024) Measuring Transcription Dynamics of Individual Genes Inside Living Cells. Methods in molecular biology (Clifton, N.J.). 2024; 2694:235-265. PM ID: 37824008
  • Matta, SK, et al. (2024) Genome-wide and targeted CRISPR screens identify RNF213 as a mediator of interferon gamma-dependent pathogen restriction in human cells. Proceedings of the National Academy of Sciences of the United States of America. 2024; 121(1):e2315865120. PM ID: 38147552
  • Cho, MG, et al. (2024) MRE11 liberates cGAS from nucleosome sequestration during tumorigenesis. Nature. 2024; 625(7995):585-592. PM ID: 38200309
  • Du, M, et al. (2024) Direct observation of a condensate effect on super-enhancer controlled gene bursting. Cell. 2024; 187(2):331-344.e17. PM ID: 38194964
  • Schmitt, J, et al. (2024) Repurposing an endogenous degradation domain for antibody-mediated disposal of cell-surface proteins. EMBO reports. 2024;. PM ID: 38287192
  • Byrnes, AE, et al. (2024) A fluorescent splice-switching mouse model enables high-throughput, sensitive quantification of antisense oligonucleotide delivery and activity. Cell reports methods. 2024; 4(1):100673. PM ID: 38171361
  • Daiki, K, et al. (2024) Blood Endocan as a Biomarker for Breast Cancer Recurrence. Preprint. 2024;. Link: Preprint
  • Koeppel, J, et al. (2024) Randomizing the human genome by engineering recombination between repeat elements. bioRxiv. 2024;. Link: bioRxiv
  • Kortleve, D, et al. (2024) TCR-engineered T-cells directed against Ropporin-1 constitute a safe and effective treatment for triple-negative breast cancer in near-clinical models. bioRxiv. 2024;. Link: bioRxiv
  • Haakonsen, DL, et al. (2024) Stress response silencing by an E3 ligase mutated in neurodegeneration. Nature. 2024; 626(8000):874-880. PM ID: 38297121
  • Gupta, P, et al. (2024) Development of pathophysiologically relevant models of sickle cell disease and β-thalassemia for therapeutic studies. Nature communications. 2024; 15(1):1794. PM ID: 38413594
  • Company, C, et al. (2024) Logical design of synthetic cis-regulatory DNA for genetic tracing of cell identities and state changes. Nature communications. 2024; 15(1):897. PM ID: 38316783
  • Yang, L, et al. (2024) Uncovering receptor-ligand interactions using a high-avidity CRISPR activation screening platform. Science advances. 2024; 10(7):eadj2445. PM ID: 38354234
  • Kubara, K, et al. (2024) Lymph node macrophages drive innate immune responses to enhance the anti-tumor efficacy of mRNA vaccines. Molecular therapy : the journal of the American Society of Gene Therapy. 2024;. PM ID: 38243602
  • Ng-Blichfeldt, J, et al. (2024) Identification of a core transcriptional program driving the human renal mesenchymal-to-epithelial transition. Developmental Cell. 2024;. Link: Developmental Cell
  • Yang, J, Cook, L & Chen, Z. (2024) Systematic evaluation of retroviral LTRs as cis-regulatory elements in mouse embryos. Cell reports. 2024; 43(3):113775. PM ID: 38381606
  • Taglini, F, et al. (2024) DNMT3B PWWP mutations cause hypermethylation of heterochromatin. EMBO reports. 2024;. PM ID: 38291337
  • Tanase-Nakao, K, et al. (2024) Genotype-Phenotype Correlations in Thirty Japanese Patients with Congenital Hypothyroidism Attributable to TG Defects. The Journal of clinical endocrinology and metabolism. 2024;. PM ID: 38373250
  • Alsouri, S, et al. (2024) Actinin-4 controls survival signaling in B cells by limiting the lateral mobility of B-cell antigen receptors. European journal of immunology. 2024;:e2350774. PM ID: 38299456
  • Ke, X, et al. (2024) Establishment of a novel minigenome system for the identification of drugs targeting Nipah virus replication. The Journal of general virology. 2024; 105(1). PM ID: 38180473

Products

Catalog Number Description Size Price Quantity Add to Cart
PB210PA-1 Super piggyBac Transposase expression vector (replaces PB200A-1) 10 µg $512
- +

Overview

Overview

Get easy, consistent transgenesis

At the heart of SBI’s PiggyBac Transposon System* is the Super PiggyBac Transposase, an engineered, hyperactive version of the enzyme that can efficiently integrate any-sized DNA insert into the genome.

Why use the PiggyBac Transposon System?

Easy, consistent transgenesis with no limits on cargo size—For transgenesis that’s easy, consistent, and not limited by cargo size, SBI’s PiggyBac Transposon System is an excellent choice. The system consists of a PiggyBac Vector and the Super PiggyBac Transposase which recognizes transposon-specific inverted terminal repeats (ITRs) and efficiently integrates the ITRs and intervening DNA into the genome at TTAA sites. The Super PiggyBac Transposase is delivered to the cell via the Super PiggyBac Transposase Expression Vector, which is co-transfected with one or more PiggyBac Vectors.

Footprint-free removal that leaves no PiggyBac sequences behind—In addition to ease-of-use, consistency, and the lack of limits on DNA insert size, what sets this system apart is the ability to reverse the integration reaction in a footprint-free way—with the Excision Only PiggyBac Transposase (Cat.# PB220PA-1), the ITRs and cargo that the Super PiggyBac Transposase integrates into the genome can be removed, leaving behind the original genomic sequence and nothing else.

  • Make transgenic cell lines with a single transfection
  • Integrate multiple PiggyBac Vectors in a single transfection
  • Insert an expression cassette into human, mouse, and rat cells
  • Deliver virtually any-sized DNA insert, from 10 – 100 kb
  • Choose from PiggyBac Vectors that express your gene-of-interest from constitutive or inducible promoters and include a variety of markers
  • Determine the number of integration events with the PiggyBac qPCR Copy Number Kit (Cat.# PBC100A-1)

Customer Agreements

Academic customers can purchase PiggyBac Transposon System components for internal research purposes for indefinite use, whereas commercial customers must sign a customer agreement for a six-month, limited-use license to evaluate the technology.

For end user license information, see the following:

* SBI is fully licensed to distribute PiggyBac vectors as a partnership with Hera BioLabs, Inc.

References

How It Works

How It Works

The PiggyBac Transposon System’s Cut-and-Paste Mechanism

The efficient PiggyBac Transposon System uses a cut-and-paste mechanism to transfer DNA from the PiggyBac Vector into the genome. If only temporary genomic integration is desired, the Excision-only PiggyBac Transposase can be transiently expressed for footprint-free removal of the insert, resulting in reconstitution of the original genome sequence.

The PiggyBac Transposon System’s cut-and-paste mechanism

Figure 1. The PiggyBac Transposon System’s cut-and-paste mechanism.

Step 1 The Super PiggyBac Transposase binds to specific inverted terminal repeats (ITRs) in the PiggyBac Cloning and Expression Vector and excises the ITRs and intervening DNA.

Step 2 The Super PiggyBac Transposase inserts the ITR-Expression Cassette-ITR segment into the genome at TTAA sites.

Step 3 The Excision-only Super PiggyBac Transposase can be used to remove the ITR-Expression Cassette-ITR segment from the genome, for footprint-free removal.

Supporting Data

Supporting Data

One transfection can integrate one or more genes that can be precisely removed

Efficient transgenesis with the Super PiggyBac Transposase and both single- and dual-promoter PiggyBac Vectors

 

Figure 2. Efficient transgenesis with the Super PiggyBac Transposase and both single- and dual-promoter PiggyBac Vectors. (Top four panels) Co-transfection with the Super PiggyBac Transposase Expression Vector (Cat.# PB210PA-1) and a Dual Promoter PiggyBac Cloning and Expression Vector (Cat.# PB513B-1) into HeLa cells demonstrates the efficient integration delivered by SBI’s PiggyBac Transposon System. After ten days of puromycin selection, only the cells co-transfected with the Super PiggyBac Transposase (+PB, right two panels) show robust growth and GFP fluorescence. (Bottom four panels) Co-transfection with the Super PiggyBac Transposase Expression Vector (Cat.# PB210PA-1) and a Single Promoter PiggyBac Cloning and Expression Vector (Cat.# PB531A-2) into HEK293 cells further demonstrates the efficient integration delivered by SBI’s PiggyBac Transposon System. After seven days of growth, the majority of cells that received the Super PiggyBac Transposase Expression Vector (+PB, right two panels) were RFP positive.

Simultaneous integration of multiple PiggyBac Vectors is also highly efficient

 

Figure 3. Simultaneous integration of multiple PiggyBac Vectors is also highly efficient. METHODS: Three different PiggyBac transposon vectors (Cat.# PB513B-1, Cat.# PB533A-2, and Cat.# PB531A-2) were co-transfected with (left panels) or without (right panels) the Super PiggyBac Transposase Expression Vector (Cat.# PB210PA-1) into Human HT1080 cells. Puromycin and neomycin selection was applied for seven days. The cells that were co-transfected with the Super PiggyBac Transposase Expression Vector were puro and neo resistant, GFP-positive, and RFP-positive. Background GFP-positive cells that are puro resistant stem from random PB513B-1 integrations during the puromycin selection. The non-PiggyBac-mediated integration rate in those cells was extremely low and no RFP-positive cells were identified.

FAQs

The Super PiggyBac Transposase Expression Vector is an engineered, hyperactive version of the enzyme used in SBI's PiggyBac Transposon System. It can efficiently integrate any-sized DNA insert into the genome, enabling easy and consistent transgenesis.
  • Delivery of virtually any-sized DNA insert, from 10 – 100 kb
  • Footprint-free removal that leaves no PiggyBac sequences behind
  • Ability to make transgenic cell lines with a single transfection
  • Capability to integrate multiple PiggyBac Vectors in a single transfection
  • Insertion of an expression cassette into human, mouse, and rat cells
  • Variety of PiggyBac Vectors with different promoters and markers
The PiggyBac Transposon System uses a cut-and-paste mechanism to transfer DNA from the PiggyBac Vector into the genome. The Super PiggyBac Transposase recognizes transposon-specific inverted terminal repeats (ITRs) and efficiently integrates the ITRs and intervening DNA into the genome at TTAA sites.
Yes, using the Excision Only PiggyBac Transposase (Cat. # PB220PA-1), the ITRs and cargo that the Super PiggyBac Transposase integrates into the genome can be removed in a footprint-free way, leaving behind the original genomic sequence and nothing else.
Academic customers can purchase PiggyBac Transposon System components for internal research purposes for indefinite use. Commercial customers must sign a customer agreement for a six-month, limited-use license to evaluate the technology. End-user license information can be found on the respective pages for academic and commercial customers.
You can contact a specialist by visiting the Contact Us page or calling 1-(888) 640-4371.

Citations

  • Brouwer, I, de Kort, MAC & Lenstra, TL. (2024) Measuring Transcription Dynamics of Individual Genes Inside Living Cells. Methods in molecular biology (Clifton, N.J.). 2024; 2694:235-265. PM ID: 37824008
  • Matta, SK, et al. (2024) Genome-wide and targeted CRISPR screens identify RNF213 as a mediator of interferon gamma-dependent pathogen restriction in human cells. Proceedings of the National Academy of Sciences of the United States of America. 2024; 121(1):e2315865120. PM ID: 38147552
  • Cho, MG, et al. (2024) MRE11 liberates cGAS from nucleosome sequestration during tumorigenesis. Nature. 2024; 625(7995):585-592. PM ID: 38200309
  • Du, M, et al. (2024) Direct observation of a condensate effect on super-enhancer controlled gene bursting. Cell. 2024; 187(2):331-344.e17. PM ID: 38194964
  • Schmitt, J, et al. (2024) Repurposing an endogenous degradation domain for antibody-mediated disposal of cell-surface proteins. EMBO reports. 2024;. PM ID: 38287192
  • Byrnes, AE, et al. (2024) A fluorescent splice-switching mouse model enables high-throughput, sensitive quantification of antisense oligonucleotide delivery and activity. Cell reports methods. 2024; 4(1):100673. PM ID: 38171361
  • Daiki, K, et al. (2024) Blood Endocan as a Biomarker for Breast Cancer Recurrence. Preprint. 2024;. Link: Preprint
  • Koeppel, J, et al. (2024) Randomizing the human genome by engineering recombination between repeat elements. bioRxiv. 2024;. Link: bioRxiv
  • Kortleve, D, et al. (2024) TCR-engineered T-cells directed against Ropporin-1 constitute a safe and effective treatment for triple-negative breast cancer in near-clinical models. bioRxiv. 2024;. Link: bioRxiv
  • Haakonsen, DL, et al. (2024) Stress response silencing by an E3 ligase mutated in neurodegeneration. Nature. 2024; 626(8000):874-880. PM ID: 38297121
  • Gupta, P, et al. (2024) Development of pathophysiologically relevant models of sickle cell disease and β-thalassemia for therapeutic studies. Nature communications. 2024; 15(1):1794. PM ID: 38413594
  • Company, C, et al. (2024) Logical design of synthetic cis-regulatory DNA for genetic tracing of cell identities and state changes. Nature communications. 2024; 15(1):897. PM ID: 38316783
  • Yang, L, et al. (2024) Uncovering receptor-ligand interactions using a high-avidity CRISPR activation screening platform. Science advances. 2024; 10(7):eadj2445. PM ID: 38354234
  • Kubara, K, et al. (2024) Lymph node macrophages drive innate immune responses to enhance the anti-tumor efficacy of mRNA vaccines. Molecular therapy : the journal of the American Society of Gene Therapy. 2024;. PM ID: 38243602
  • Ng-Blichfeldt, J, et al. (2024) Identification of a core transcriptional program driving the human renal mesenchymal-to-epithelial transition. Developmental Cell. 2024;. Link: Developmental Cell
  • Yang, J, Cook, L & Chen, Z. (2024) Systematic evaluation of retroviral LTRs as cis-regulatory elements in mouse embryos. Cell reports. 2024; 43(3):113775. PM ID: 38381606
  • Taglini, F, et al. (2024) DNMT3B PWWP mutations cause hypermethylation of heterochromatin. EMBO reports. 2024;. PM ID: 38291337
  • Tanase-Nakao, K, et al. (2024) Genotype-Phenotype Correlations in Thirty Japanese Patients with Congenital Hypothyroidism Attributable to TG Defects. The Journal of clinical endocrinology and metabolism. 2024;. PM ID: 38373250
  • Alsouri, S, et al. (2024) Actinin-4 controls survival signaling in B cells by limiting the lateral mobility of B-cell antigen receptors. European journal of immunology. 2024;:e2350774. PM ID: 38299456
  • Ke, X, et al. (2024) Establishment of a novel minigenome system for the identification of drugs targeting Nipah virus replication. The Journal of general virology. 2024; 105(1). PM ID: 38180473